GB0001448D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0001448D0
GB0001448D0 GBGB0001448.0A GB0001448A GB0001448D0 GB 0001448 D0 GB0001448 D0 GB 0001448D0 GB 0001448 A GB0001448 A GB 0001448A GB 0001448 D0 GB0001448 D0 GB 0001448D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0001448.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0001448(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0001448.0A priority Critical patent/GB0001448D0/en
Publication of GB0001448D0 publication Critical patent/GB0001448D0/en
Priority to CO01003434A priority patent/CO5261584A1/es
Priority to MYPI20010226A priority patent/MY155269A/en
Priority to PL356297A priority patent/PL207642B1/pl
Priority to JP2001553825A priority patent/JP3978338B2/ja
Priority to ARP010100247A priority patent/AR027253A1/es
Priority to ES01905671T priority patent/ES2274865T5/es
Priority to MXPA02007091A priority patent/MXPA02007091A/es
Priority to PT01905671T priority patent/PT1248804E/pt
Priority to AU33697/01A priority patent/AU772949B2/en
Priority to KR1020027009374A priority patent/KR100697126B1/ko
Priority to PE2001000065A priority patent/PE20011219A1/es
Priority to NZ519936A priority patent/NZ519936A/en
Priority to IL15055101A priority patent/IL150551A0/xx
Priority to RU2002121649/13A priority patent/RU2264413C2/ru
Priority to SK1035-2002A priority patent/SK288054B6/sk
Priority to CA2396212A priority patent/CA2396212C/en
Priority to DE60124863T priority patent/DE60124863T3/de
Priority to DK01905671.2T priority patent/DK1248804T4/da
Priority to AT01905671T priority patent/ATE346868T1/de
Priority to CN018039529A priority patent/CN1395581B/zh
Priority to BR0107661-2A priority patent/BR0107661A/pt
Priority to US10/181,324 priority patent/US20030124617A1/en
Priority to EP01905671A priority patent/EP1248804B2/en
Priority to TR2002/01780T priority patent/TR200201780T2/xx
Priority to CZ20022531A priority patent/CZ302738B6/cs
Priority to PCT/EP2001/000591 priority patent/WO2001053353A2/en
Priority to SI200130698T priority patent/SI1248804T2/sl
Priority to HU0204156A priority patent/HUP0204156A3/hu
Priority to HK03102022.5A priority patent/HK1050013A1/zh
Priority to IL150551A priority patent/IL150551A/en
Priority to NO20023266A priority patent/NO329816B1/no
Priority to ZA2002/05659A priority patent/ZA200205659B/en
Priority to US11/484,472 priority patent/US7491392B2/en
Priority to CY20061101860T priority patent/CY1107989T1/el
Priority to JP2007000148A priority patent/JP2007097598A/ja
Priority to US12/351,007 priority patent/US20090232803A1/en
Priority to US13/044,918 priority patent/US20110182894A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
GBGB0001448.0A 2000-01-21 2000-01-21 Organic compounds Ceased GB0001448D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
CO01003434A CO5261584A1 (es) 2000-01-21 2001-01-18 Anticuerpos para il-1 humana
MYPI20010226A MY155269A (en) 2000-01-21 2001-01-18 ANTIBODIES TO HUMAN IL-1ß
HU0204156A HUP0204156A3 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
HK03102022.5A HK1050013A1 (zh) 2000-01-21 2001-01-19 抗人IL-1β抗體
DE60124863T DE60124863T3 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
CN018039529A CN1395581B (zh) 2000-01-21 2001-01-19 重组人白细胞介素-1β抗体
ARP010100247A AR027253A1 (es) 2000-01-21 2001-01-19 Anticuerpos para il-1beta humana
ES01905671T ES2274865T5 (es) 2000-01-21 2001-01-19 Anticuerpos recombinantes para la interleuquina-1 beta humana.
MXPA02007091A MXPA02007091A (es) 2000-01-21 2001-01-19 Anticuerpos para il-1b humana.
PT01905671T PT1248804E (pt) 2000-01-21 2001-01-19 Anticorpos contra il-1b humana
AU33697/01A AU772949B2 (en) 2000-01-21 2001-01-19 Antibodies to human IL-1beta
KR1020027009374A KR100697126B1 (ko) 2000-01-21 2001-01-19 인간 ＩＬ-1β에 대한 항체
PE2001000065A PE20011219A1 (es) 2000-01-21 2001-01-19 ANTICUERPOS PARA IL-1ß HUMANA
NZ519936A NZ519936A (en) 2000-01-21 2001-01-19 Antibodies to human Interleukin-1
IL15055101A IL150551A0 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
RU2002121649/13A RU2264413C2 (ru) 2000-01-21 2001-01-19 РЕКОМБИНАНТНОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ 1β
SK1035-2002A SK288054B6 (sk) 2000-01-21 2001-01-19 Antibody to IL-1 beta, IL-1 beta binding molecule, its use and process for production, first DNA construct, expression vector and pharmaceutical composition
CA2396212A CA2396212C (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
PL356297A PL207642B1 (pl) 2000-01-21 2001-01-19 Przeciwciało wiążące IL-1ß, konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
DK01905671.2T DK1248804T4 (da) 2000-01-21 2001-01-19 Rekombinante antistoffer mod humant interleukin-1-beta
AT01905671T ATE346868T1 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
JP2001553825A JP3978338B2 (ja) 2000-01-21 2001-01-19 ヒトＩＬ−１βに対する抗体
BR0107661-2A BR0107661A (pt) 2000-01-21 2001-01-19 Anticorpos para il-1/ß humana
US10/181,324 US20030124617A1 (en) 2000-01-21 2001-01-19 Antibodies to human il 1-beta
EP01905671A EP1248804B2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
TR2002/01780T TR200201780T2 (tr) 2000-01-21 2001-01-19 İnsanlara özgü interlökin-1 beta' ya karşı rekombinant antikorlar
CZ20022531A CZ302738B6 (cs) 2000-01-21 2001-01-19 Protilátka proti IL-1beta tvorená molekulou vázající IL-1beta, tato molekula pro použití jako lécivo, použití této molekuly pro výrobu léciva, odpovídající DNA konstrukty a expresní vektor, zpusob prípravy uvedené molekuly a farmaceutická kompozice o
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta
SI200130698T SI1248804T2 (sl) 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta
IL150551A IL150551A (en) 2000-01-21 2002-07-02 Recombinant antibody against interleukin - 1 human beta, pharmaceutical compounds that include it, a construct of DNA that encodes it, a process for its preparation and uses in drug preparation
NO20023266A NO329816B1 (no) 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning
ZA2002/05659A ZA200205659B (en) 2000-01-21 2002-07-16 Recombinant antibodies to human interleukin-1 beta
US11/484,472 US7491392B2 (en) 2000-01-21 2006-07-11 Antibodies to human IL-1β
CY20061101860T CY1107989T1 (el) 2000-01-21 2006-12-29 Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
JP2007000148A JP2007097598A (ja) 2000-01-21 2007-01-04 ヒトＩＬ−１βに対する抗体
US12/351,007 US20090232803A1 (en) 2000-01-21 2009-01-09 Antibodies to human il-1beta
US13/044,918 US20110182894A1 (en) 2000-01-21 2011-03-10 Methods of treating diabetes using IL-1beta antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Publications (1)

Publication Number Publication Date
GB0001448D0 true GB0001448D0 (en) 2000-03-08

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0001448.0A Ceased GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Country Status (33)

Country Link
US (4) US20030124617A1 (enExample)
EP (1) EP1248804B2 (enExample)
JP (2) JP3978338B2 (enExample)
KR (1) KR100697126B1 (enExample)
CN (1) CN1395581B (enExample)
AR (1) AR027253A1 (enExample)
AT (1) ATE346868T1 (enExample)
AU (1) AU772949B2 (enExample)
BR (1) BR0107661A (enExample)
CA (1) CA2396212C (enExample)
CO (1) CO5261584A1 (enExample)
CY (1) CY1107989T1 (enExample)
CZ (1) CZ302738B6 (enExample)
DE (1) DE60124863T3 (enExample)
DK (1) DK1248804T4 (enExample)
ES (1) ES2274865T5 (enExample)
GB (1) GB0001448D0 (enExample)
HK (1) HK1050013A1 (enExample)
HU (1) HUP0204156A3 (enExample)
IL (2) IL150551A0 (enExample)
MX (1) MXPA02007091A (enExample)
MY (1) MY155269A (enExample)
NO (1) NO329816B1 (enExample)
NZ (1) NZ519936A (enExample)
PE (1) PE20011219A1 (enExample)
PL (1) PL207642B1 (enExample)
PT (1) PT1248804E (enExample)
RU (1) RU2264413C2 (enExample)
SI (1) SI1248804T2 (enExample)
SK (1) SK288054B6 (enExample)
TR (1) TR200201780T2 (enExample)
WO (1) WO2001053353A2 (enExample)
ZA (1) ZA200205659B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1519747A4 (en) * 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CA2963828A1 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
WO2008145664A1 (en) * 2007-05-29 2008-12-04 Novartis Ag New indications for anti- il-i-beta therapy
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
HRP20130042T1 (hr) * 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
AU2009289547A1 (en) 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
WO2012034039A2 (en) * 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
SMT201900296T1 (it) 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
SG10201708562VA (en) 2012-02-13 2017-12-28 Agency Science Tech & Res IL-1β Neutralizing Human Monoclonal Antibodies
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN116063489B (zh) * 2022-10-21 2026-01-30 杭州靶向食品科技有限公司 一种治疗痛风的单克隆抗体及其相应的组合物
JP2026521932A (ja) 2023-06-28 2026-07-02 フィル リバーズ テクノロジー カンパニー リミテッド Ｐｄ－ｌ１及びｉｌ－１を標的とする二重特異性抗体及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NO20023266L (no) 2002-08-28
SK10352002A3 (sk) 2003-03-04
EP1248804B2 (en) 2009-12-02
SK288054B6 (sk) 2013-03-01
KR20020073178A (ko) 2002-09-19
US20060251660A1 (en) 2006-11-09
CY1107989T1 (el) 2013-09-04
JP3978338B2 (ja) 2007-09-19
AR027253A1 (es) 2003-03-19
TR200201780T2 (tr) 2003-01-21
WO2001053353A3 (en) 2002-04-04
NO329816B1 (no) 2010-12-27
JP2007097598A (ja) 2007-04-19
DE60124863T2 (de) 2007-04-26
DK1248804T3 (da) 2007-02-26
NZ519936A (en) 2004-02-27
CN1395581A (zh) 2003-02-05
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
CZ20022531A3 (cs) 2002-10-16
MXPA02007091A (es) 2002-12-13
EP1248804B1 (en) 2006-11-29
CO5261584A1 (es) 2003-03-31
DE60124863T3 (de) 2010-05-20
CN1395581B (zh) 2010-10-13
MY155269A (en) 2015-09-30
IL150551A0 (en) 2003-02-12
NO20023266D0 (no) 2002-07-05
ES2274865T3 (es) 2007-06-01
RU2264413C2 (ru) 2005-11-20
AU3369701A (en) 2001-07-31
US20030124617A1 (en) 2003-07-03
BR0107661A (pt) 2002-11-19
CA2396212A1 (en) 2001-07-26
PL207642B1 (pl) 2011-01-31
RU2002121649A (ru) 2004-03-10
WO2001053353A2 (en) 2001-07-26
PL356297A1 (en) 2004-06-28
ES2274865T5 (es) 2010-04-19
ATE346868T1 (de) 2006-12-15
DK1248804T4 (da) 2010-04-06
EP1248804A2 (en) 2002-10-16
AU772949B2 (en) 2004-05-13
JP2003520595A (ja) 2003-07-08
KR100697126B1 (ko) 2007-03-20
SI1248804T2 (sl) 2010-04-30
US20110182894A1 (en) 2011-07-28
HUP0204156A2 (hu) 2003-03-28
PE20011219A1 (es) 2001-12-17
US7491392B2 (en) 2009-02-17
SI1248804T1 (sl) 2007-06-30
HUP0204156A3 (en) 2005-09-28
ZA200205659B (en) 2003-12-31
IL150551A (en) 2010-11-30
PT1248804E (pt) 2007-02-28
US20090232803A1 (en) 2009-09-17
CA2396212C (en) 2013-04-02

Similar Documents

Publication Publication Date Title
AU8389101A (en) Organic compounds
GB0010955D0 (en) Organic compounds
GB0006398D0 (en) Organic compounds
GB0003111D0 (en) Organic compounds
GB0008694D0 (en) Organic compounds
GB0008785D0 (en) Organic compounds
GB0002100D0 (en) Organic compounds
AU3458802A (en) Organic compounds
GB0007108D0 (en) Organic compounds
GB0007911D0 (en) Organic compounds
GB0002740D0 (en) Organic compounds
GB0009037D0 (en) Organic compounds
GB0009054D0 (en) Organic compounds
GB0009053D0 (en) Organic compounds
GB0009055D0 (en) Organic compounds
GB0010200D0 (en) Organic compounds
GB0001929D0 (en) Organic compounds
GB0002101D0 (en) Organic compounds
GB0010205D0 (en) Organic compounds
GB0010210D0 (en) Organic compounds
GB0001697D0 (en) Organic compounds
GB0009031D0 (en) Organic compounds
GB0010208D0 (en) Organic compounds
GB0010956D0 (en) Organic compounds
GB0006735D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)